TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17211970

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.2% with the On-Q PAINBUSTER system
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 mg morphine + 120 mg ketorolac + saline solution up to 96 ml with an elastomeric pump i.v.
Number of subjects: 20
Study: 14604928

Group type: EXPERIMENTAL
Intervention: Chloroquine and proguanil
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Atovaquone and proguanil
Number of subjects: 623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study: 10980174

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for 5 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for 10 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ofloxacin therapy for 3 days
Number of subjects: 49
Study: 8931409

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment for 2 years
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo treatment for 2 years
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 61
Study: 1422751

Group type: EXPERIMENTAL
Intervention: Loop ileostomy
Number of subjects: 45

Group type: COMPARATOR
Intervention: No ileostomy
Number of subjects: 45
Study: 6233547

Group type: EXPERIMENTAL
Intervention: Inhaling a combined preparation of fenoterol 200 micrograms and ipratropium bromide 80 micrograms (Duovent)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inhaling 200 micrograms of salbutamol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inhaling a similar dose of fenoterol
Number of subjects: 24
Study: 30807738

Group type: EXPERIMENTAL
Intervention: Eight-week group dialogue and empathy intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study: 28878156

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 50

Group type: COMPARATOR
Intervention: Povidone-iodine (active comparator)
Number of subjects: 50
Study: 25852025

Group type: EXPERIMENTAL
Intervention: Hi-SDS breakfasts
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lo-SDS breakfast
Number of subjects: 16
Study: 23771480

Group type: EXPERIMENTAL
Intervention: Intervention wards (trained in six core strategies for six months)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intervention wards
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control wards
Number of subjects: 88
Study: 21131468

Group type: EXPERIMENTAL
Intervention: Interferon gamma‐1b
Number of subjects: 822
Study: 19266825

Group type: EXPERIMENTAL
Intervention: Rocuronium under sevoflurane
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cisatracurium under sevoflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rocuronium under TIVA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cisatracurium under TIVA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: TIVA (Propofol)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rocuronium and Cisatracurium
Number of subjects: 80
Study: 18020935

Group type: EXPERIMENTAL
Intervention: Computer-tailored dietary fat intake intervention (50-min session)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 304
Study: 15074388

Group type: EXPERIMENTAL
Intervention: Brief inventory for diagnosis and monitoring of GORD symptoms
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Omeprazole treatment
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 558
Study: 11237160

Group type: COMPARATOR
Intervention: Leisure therapy
Number of subjects: 466

Group type: COMPARATOR
Intervention: Conventional occupational therapy (OT)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 466
Study: 9673264

Group type: EXPERIMENTAL
Intervention: Acellular vaccine containing pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Natural infection with PT and FHA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acellular vaccine
Number of subjects: 24
Study: 8079053

Group type: EXPERIMENTAL
Intervention: Defibrillation by emergency medical technicians (EMTs)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Defibrillation by emergency physicians (EPs)
Number of subjects: 159
Study: 2809409

Group type: EXPERIMENTAL
Intervention: Passages with combined semantic and syntactic modifications
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Passages with syntactic modifications alone
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Passages with semantic modifications alone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group reading a social studies passage without change
Number of subjects: 92
Study: 812887

Group type: EXPERIMENTAL
Intervention: Glucose system (glucose alone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid system (83% Intralipid and 17% glucose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid system
Number of subjects: 0
Study: 31196175

Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 120
Study: 28818057

Group type: EXPERIMENTAL
Intervention: Counselling sessions with a physiotherapist during pulmonary rehabilitation (5 sessions)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard pulmonary rehabilitation program (12 weeks)
Number of subjects: 56
Study: 25822691

Group type: EXPERIMENTAL
Intervention: Comprehensive Surgical Coaching (CSC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Training (CT)
Number of subjects: 20
Study: 22866680

Group type: EXPERIMENTAL
Intervention: Making Socially Accepting Inclusive Classrooms (MOSAIC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Contingency management training (COMET)
Number of subjects: 24
Study: 21296481

Group type: EXPERIMENTAL
Intervention: HM3 lithotripter
Number of subjects: 820

Group type: COMPARATOR
Intervention: MODULITH® SLX-F2 lithotripter
Number of subjects: 820
Study: 18850516

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 microg initial dose, followed by 50 microg doses at 3-6 hour intervals)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Foley catheter and oral misoprostol (100 microg at 4-6 hour intervals)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 232

Group type: COMPARATOR
Intervention: Foley catheter and oral misoprostol
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol and Foley catheter with oral misoprostol
Number of subjects: 232
Study: 17084102

Group type: EXPERIMENTAL
Intervention: Silver-impregnated lens case
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard lens case
Number of subjects: 80
Study: 14763920

Group type: EXPERIMENTAL
Intervention: Peroral oestradiol plus CPA (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transdermal oestradiol plus CPA (n=12)
Number of subjects: 24
Study: 11485131

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9164314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg twice a day)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Lamivudine plus Loviride (150 mg twice a day plus 100 mg three times a day)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1840
Study: 7696153

Group type: EXPERIMENTAL
Intervention: Automated computer‐assisted image analysis (BIOCOM 500) for BrdU labelling index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated image analysis for estrogen receptor (ER) content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated image analysis for progesterone receptor (PR) content
Number of subjects: 0
Study: 3427825

Group type: EXPERIMENTAL
Intervention: Keyhole limpet haemocyanin (KLH) 250 micrograms
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Keyhole limpet haemocyanin (KLH) 2.5 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rabies vaccine (RV) 170 micrograms
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rabies vaccine (RV) 680 micrograms
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 120
Study: 31782028

Group type: EXPERIMENTAL
Intervention: Competitive athletes
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Baseball players, cyclists, and wrestlers
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Basketball players
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Baseball players, cyclists, rowers, and wrestlers
Number of subjects: 611
Study: 29976359

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus‐eluting stents
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1905

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1905
Study: 28101631

Group type: EXPERIMENTAL
Intervention: Drill guide technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Free-hand technique
Number of subjects: 24
Study: 25623323

Group type: EXPERIMENTAL
Intervention: High inferior mesenteric artery ligation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low inferior mesenteric artery ligation
Number of subjects: 200
Study: 24094789

Group type: EXPERIMENTAL
Intervention: Behavioral activation (12-14 sessions within a 12-week intervention period)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral activation (immediate start group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral activation (delayed start group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study: 20174902

Group type: EXPERIMENTAL
Intervention: SMS-based physical activity intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Minimal contact control
Number of subjects: 88
Study: 17951619

Group type: EXPERIMENTAL
Intervention: FeNO measurement with a portable nitric oxide analyzer
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: FeNO values > 19 ppb
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: FeNO values > 25 ppb
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: FeNO measurement
Number of subjects: 961
Study: 16977262

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 104

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 104

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 104
Study: 12950410

Group type: EXPERIMENTAL
Intervention: 250 mg levofloxacin once a day over 10 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 36
Study: 10888969

Group type: EXPERIMENTAL
Intervention: Aerobic exercise only
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Behavioral weight management program, including exercise
Number of subjects: 133

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 133
Study: 9162608

Group type: EXPERIMENTAL
Intervention: Higher 120-min proinsulin response to glucose during initial OGTT
Number of subjects: 59

Group type: COMPARATOR
Intervention: Initial fasting plasma glucose values
Number of subjects: 59

Group type: COMPARATOR
Intervention: Initial 120-min plasma glucose values
Number of subjects: 59
Study: 8091868

Group type: COMPARATOR
Intervention: 15 mg methotrexate (MTX) per week
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 25 mg methotrexate (MTX) per week
Number of subjects: 168
Study: 2855325

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Sequential chemotherapy using three different drug-combinations
Number of subjects: 121
Study: 29650440

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and macrogol
Number of subjects: 129

Group type: COMPARATOR
Intervention: Macrogol and matching placebo
Number of subjects: 129
Study: 27665002

Group type: EXPERIMENTAL
Intervention: Scattered-site Housing First (SHF) with Assertive Community Treatment
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Congregate Housing First (CHF) with on-site supports
Number of subjects: 165

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 165
Study: 25725780

Group type: EXPERIMENTAL
Intervention: TAP block with 20 ml 0.25 % levobupivacaine (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-TAP group (no TAP block)
Number of subjects: 40
Study: 23736089

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pentax AWS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Storz C‐MAC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GlideScope Ranger
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: McGrath Series5
Number of subjects: 20
Study: 21483384

Group type: EXPERIMENTAL
Intervention: 2 mg physostigmine in 250 mL N/S 0.9% (Physo group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 250 mL N/S 0.9% placebo (Control group)
Number of subjects: 80
Study: 18155759

Group type: EXPERIMENTAL
Intervention: Syntac Assortment (SY)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Adaper Prompt L‐Pop (PLP)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: iBond Gluma inside (IB)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (PB)
Number of subjects: 167
Study: 16579002

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 15107914

Group type: EXPERIMENTAL
Intervention: Non-fluoridated dentifrice with 20% sucrose solution dripped 10 times a day
Number of subjects: 13
Study: 10688723

Group type: EXPERIMENTAL
Intervention: Narrow-band UVB phototherapy combined with topical tazarotene 0.05% applied once daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Narrow-band UVB phototherapy (monotherapy)
Number of subjects: 10
Study: 7551562

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 25
Study: 2394301

Group type: EXPERIMENTAL
Intervention: Fumaric acid combination (FAC-EC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dimethylfumaric acid esters (DMFAE-EC)
Number of subjects: 45
Study: 6997522

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1012
Study: 30716188

Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Nurse counselling
Number of subjects: 189

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Peer support and Nurse counselling
Number of subjects: 189
Study: 28905478

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks, with potential increase to 150 mg every 2 weeks at week 12 if LDL cholesterol levels were ≥1.8 mmol/L at week 8.
Number of subjects: 517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study: 25783974

Group type: EXPERIMENTAL
Intervention: Everolimus with complete calcineurin inhibitor elimination
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard cyclosporine immunosuppression
Number of subjects: 115
Study: 23935818

Group type: EXPERIMENTAL
Intervention: Multimedia software for teaching skin flap surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard text‐based print article
Number of subjects: 50
Study: 20671295

Group type: EXPERIMENTAL
Intervention: Intranasal d-amphetamine (0, 16, 24, and 32 mg/70 kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral d-amphetamine (equal doses to intranasal)
Number of subjects: 0
Study: 19525742

Group type: EXPERIMENTAL
Intervention: Vietnam combat veterans with PTSD
Number of subjects: 124

Group type: COMPARATOR
Intervention: Vietnam combat veterans without PTSD
Number of subjects: 124
Study: 17954514

Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Intramuscular haloperidol plus promethazine
Number of subjects: 300
Study: 15311032

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 11490143

Group type: EXPERIMENTAL
Intervention: SLPI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lactoferrin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Total protein
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Age and Gender
Number of subjects: 45
Study: 10181019

Group type: EXPERIMENTAL
Intervention: Outcome information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both sorts of information
Number of subjects: 0

Group type: COMPARATOR
Intervention: No information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of outcome information and self-efficacy enhancing information
Number of subjects: 0
Study: 7589026

Group type: EXPERIMENTAL
Intervention: 200 mg controlled-release metoprolol
Number of subjects: 11
Study: 2912356

Group type: EXPERIMENTAL
Intervention: Histamine-induced bronchospasm with theophylline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Histamine-induced bronchospasm without theophylline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Saline-induced bronchospasm with theophylline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Saline-induced bronchospasm without theophylline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mild bronchospasm
Number of subjects: 10
Study: 1158628

Group type: EXPERIMENTAL
Intervention: Protriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study: 31707832

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 31299610

Group type: EXPERIMENTAL
Intervention: Sirolimus treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 121
Study: 28663046

Group type: EXPERIMENTAL
Intervention: Active VNS
Number of subjects: 96

Group type: COMPARATOR
Intervention: Inactive VNS (Control)
Number of subjects: 96
Study: 26032788

Group type: EXPERIMENTAL
Intervention: Guided affective imagery
Number of subjects: 15
Study: 23777744

Group type: EXPERIMENTAL
Intervention: Protocol B (100 kV protocol at pitch 3.2 with a cardiac bowtie‐shaped filter)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Protocol A (standard 100 kV protocol at pitch 2.8)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Protocol B
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iterative reconstruction
Number of subjects: 100
Study: 21784729

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg plus MTX
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg plus MTX
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg plus placebo
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg plus placebo
Number of subjects: 444

Group type: COMPARATOR
Intervention: placebo plus MTX
Number of subjects: 444
Study: 19525747

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 90
Study: 16944674

Group type: EXPERIMENTAL
Intervention: 10 mg of zolpidem (Z)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study: 15351162

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil introduction with cyclosporine reduction (target trough levels 2-4 microg/ml)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group with unchanged immunosuppression
Number of subjects: 161
Study: 11933416

Group type: EXPERIMENTAL
Intervention: Self‐adherent, hydroactive, polyurethane dressing alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Polyurethane plus compression
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Silicone sheeting plus compression
Number of subjects: 12

Group type: COMPARATOR
Intervention: Compression alone
Number of subjects: 12
Study: 9497765

Group type: EXPERIMENTAL
Intervention: IPS-Empress full-porcelain crowns
Number of subjects: 34
Study: 8441139

Group type: COMPARATOR
Intervention: Indomethacin 50 mg tid
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 60 mg intramuscularly
Number of subjects: 27
Study: 3911309

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasonography
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 181
Study: 30173873

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 323

Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Maternal diet during pregnancy
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Solid food introduction
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Breastfeeding and child race/ethnicity interaction
Number of subjects: 323
Study: 27473180

Group type: EXPERIMENTAL
Intervention: Samvedana Plus intervention (multi-level intervention programme)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (village clusters not receiving the intervention initially)
Number of subjects: 800
Study: 24587570

Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27